Compositions for the treatment of pulmonary fibrosis

A compound of the formula:

• or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof,
• wherein:
• B is selected from the group consisting of:
• R1, R3 and R4 are independently C, CH, CH2, O, N, NH or S,
• R2 is C, CH, CH2, N, NH, C—CF3, CH—CF3 or C═O;
• R5 to R9 are independently C or N;
• Q is independently selected from halo, alkyl, hydroxy, amino and substituted amino;
• n is 0, 1, 2, 3, 4 or 5;
• D is:
• R10 to R14 are independently C, N, O or S;
• T is independently selected from C1-6alkyl, halo, C0-6alkyl carboxylic acid, amino, hydroxy and C1-6alkoxy;
• and
• m is 0, 1, 2, 3 or 4,
• wherein D cannot be unsubstituted phenyl, and Q cannot be hydroxy when n is 1 and R5 to R9 are all C.